Analyst Ratings for Crescent Biopharma Inc (CBIO)
CBIO Rating Summary
CBIO Price Target Summary
- Highest: $35.00 (Guggenheim)
- Lowest: $30.00 (Stifel)
- Average: $32.50
* Over Last 12-Mos
Overall Rating:
BUY
Rating Trend:
Avg. $ Target:
$32.50 (+67.4%)
* Over Last 12-Mos
Rating Score: 7.1 / 10
Percentile Rank: 75%
Avg. $ Target:
$32.50 (+67.4%)
* Over Last 12-Mos
Rating Score: 7.1 / 10
Percentile Rank: 75%
| Date | Firm | Analyst | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 8/22/2026 | TD Cowen | Tyl | New Coverage | Buy (N/A) |
N/A (N/A) |
16.23 (19.41) |
19.59% | Details |
| 6/1/2026 | H.C. Wainwright » Updated 7/31/2026 |
Mitchell S. Kapoor | Downgrade | Neutral (Buy) |
N/A (N/A) |
20.65 (19.41) |
-6% | Details |
 |
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
